Organogenesis sees FY25 revenue $480M-$535M, consensus $472.94M

Sees FY25 adjusted EBITDA $43.6M-$83.2M. Gillheeney, Sr. continued: “We expect to meet a key strategic milestone in 2025 by delivering the ReNu BLA submission by the end of the year. We believe this is a transformational opportunity for Organogenesis (ORGO) in that, if approved, ReNu will potentially address an unmet clinical need for all patients suffering from knee OA.”